SCHEDULE: Frazier Life Sciences Group Discloses 6.57% Stake in VOR Biopharma

Frazier Life Sciences and its affiliated entities have disclosed a collective beneficial ownership of 6.57% in VOR Biopharma Inc.'s common stock, signaling a significant institutional investment.

Summary

• Frazier Life Sciences Public Fund, L.P., along with its related entities FHMLSP, L.P. and FHMLSP, L.L.C., beneficially owns 2,258,001 shares of VOR Biopharma Inc. common stock, representing 5.8% of the class.
• Frazier Life Sciences XI, L.P., and its related entities FHMLS XI, L.P. and FHMLS XI, L.L.C., beneficially owns 21,114 shares, representing 0.1% of the class.
• Frazier Life Sciences XII, L.P., and its related entities FHMLS XII, L.P. and FHMLS XII, L.L.C., beneficially owns 264,824 shares, representing 0.7% of the class.
• Collectively, the Frazier Life Sciences group beneficially owns 2,543,939 shares, which represents approximately 6.57% of VOR Biopharma Inc.'s common stock.
• The percentage ownership is calculated based on 38,720,196 shares of Common Stock outstanding as of December 18, 2025.
• The Reporting Persons have shared voting and dispositive power over their respective holdings.
• The investment is stated to be for passive purposes, not for changing or influencing the control of the issuer.

Sentiment

Score: 7

Explanation: The disclosure of a significant passive stake by a prominent life sciences investment firm is generally a positive indicator, suggesting institutional confidence in the company's value and prospects. It does not, however, provide operational or financial performance details.

Positives

• A significant institutional investor, Frazier Life Sciences, has disclosed a substantial stake of 6.57% in VOR Biopharma, which can be interpreted as a vote of confidence in the company's long-term prospects.
• The investment is passive, indicating a belief in the current management and strategic direction without intent to influence control.

Future Outlook

NA

Industry Context

The disclosure of a significant stake by a specialized life sciences investment firm like Frazier Life Sciences in a biopharma company like VOR Biopharma is a common occurrence in the sector. Such investments often reflect a long-term view on the potential of the company's pipeline or technology, aligning with the high-risk, high-reward nature of the biotechnology industry. It suggests that experienced investors see value in VOR Biopharma's current trajectory.

Comparison to Industry Standards

• Institutional ownership levels vary widely across the biopharma industry, but a 6.57% stake by a reputable life sciences fund is a notable position, often exceeding the average initial stakes taken by new institutional investors in smaller-cap biotech firms.
• While specific comparable companies or projects are not mentioned in the filing, the investment by Frazier Life Sciences, known for its focus on healthcare and life sciences, suggests a strategic alignment with VOR Biopharma's sector-specific growth potential.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional investor could positively influence investor sentiment and potentially the stock price, signaling external validation of the company's value.
• Management: The passive nature of the investment suggests Frazier Life Sciences is supportive of the current management and strategic direction, which could provide stability.

Key Dates

Keywords

VOR Biopharma, Frazier Life Sciences, Institutional Ownership, Biopharma Investment, Schedule 13G, Common Stock, Beneficial Ownership